FY2022 Q3 Financial and R&D Update

Major R&D Milestones (3ADCs) Project ENHERTUⓇ Daiichi-Sankyo As of Jan 2023 BC • • • Target Indication [phase, study name] HER2+, 2L [Ph3, DESTINY-Breast03] HER2 low, post chemo [Ph3, DESTINY-Breast04] HER2 low, chemo naïve [Ph3, DESTINY-Breast06] HER2+, 2L [Ph2, DESTINY-Gastric02, EU] HER2 mutant, 2L [Ph2, DESTINY-Lung01, 02] GC • NSCLC • CRC • HER2+, 3L [Ph2, DESTINY-CRC02] FY2022 H2 FY2023 H1 H2 • Approved (JP) • Approved (EU) • Approval anticipated (JP) • Approved (EU) • ⚫ TLR anticipated . Filing accepted (JP/EU) • Approval anticipated (JP) • Approval anticipated (EU) • TLR obtained • 2/3L [Ph3, TROPION-Lung01] NSCLC Dato-DXd • 1L [Ph3, TROPION-Lung07] • Study started BC • TNBC, adjuvant* [Ph3, TROPION-Breast03] • Study started • EGFR mutated, 3L HER3-DXd NSCLC [Registrational Ph2, HERTHENA-Lung01] • TLR anticipated • TLR anticipated Bold: update from FY2022 Q2 BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TLR: Top Line Results, TNBC: triple-negative breast cancer Timeline indicated is based on the current forecast and subject to change. * Adjuvant therapy for patients with TNBC who have residual disease after neoadjuvant therapy 35

View entire presentation